The speaker says a virtual-cell platform might generate consulting revenue, but investors, particularly in Europe's more conservative venture-capital ecosystem, more readily understand a business that eventually develops a drug.

“But turning this actually into a monetary thing is not as obvious. I mean, there might be some sort of consulting business, but if you say you build a virtual cell platform, typically what investors understand, and this is maybe even more so in the more conservative VC ecosystem in Europe than in US, is that at some point you develop a drug, and then, you know, it's a clear thing.”